Cargando…
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating disorder that results in frequent exacerbations and impacts quality of life. It represents a growing burden of health care cost, both from societal and economic perspectives. Short- and long-acting bronchodilators remain the...
Autores principales: | Muruganandan, Sanjeevan, Jayaram, Lata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476436/ https://www.ncbi.nlm.nih.gov/pubmed/26124657 http://dx.doi.org/10.2147/COPD.S54154 |
Ejemplares similares
-
Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016) -
Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023) -
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
por: Buhl, Roland, et al.
Publicado: (2015) -
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
por: Derom, Eric, et al.
Publicado: (2019) -
Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)